A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

This study is for children and teenagers under 18 years old who have received either a solid organ transplant (like a kidney or liver) or a stem cell transplant. Currently, the transplant you received must be working well.

To join, you must have a confirmed CMV infection. This means tests have shown a certain level of the CMV virus in your blood. The doctors will also check your blood to make sure your infection is at a level that meets the study's requirements.

There are also some health checks you need to pass, like having certain levels of blood cells (white blood cells, platelets, and red blood cells) and good kidney function. If you're under 6 years old, you'll also need to have been born at full-term and weigh at least 5 kilograms.

If you join the study, you'll take the medicine maribavir every day for 8 weeks. This medicine will be given as a tablet or a liquid form, depending on what's best for you. During this time, you'll have regular visits to your doctor to check your health and how the medicine is working. After the 8 weeks of treatment, there will be a follow-up period of 12 weeks. During these 12 weeks, you'll still need to visit your doctor for check-ups to make sure you're doing well and that the CMV infection is staying under control. The doctors will monitor your health throughout the entire study.